Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$102.89 +1.3%	$106.70	$72.02 ▼ $139.13	$5.07B	0.47	677,064 shs	650,414 shs
LNTH Lantheus	$78.99 +1.4%	$87.25	$73.11 ▼ $126.89	$5.46B	0.11	1.02 million shs	942,075 shs
NUVL Nuvalent	$75.53 -0.7%	$73.82	$55.54 ▼ $113.51	$5.42B	1.34	493,725 shs	360,890 shs
OCUL Ocular Therapeutix	$8.33 +0.4%	$7.85	$5.79 ▼ $11.78	$1.33B	1.42	1.44 million shs	1.64 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-3.16%	-5.04%	-18.85%	+35.35%
LNTH Lantheus	0.00%	-1.43%	+2.81%	-19.16%	-2.64%
NUVL Nuvalent	0.00%	-3.05%	-0.46%	-3.12%	-3.29%
OCUL Ocular Therapeutix	0.00%	-6.93%	+9.61%	+10.92%	+51.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6368 of 5 stars	4.5	2.0	4.5	1.3	4.2	0.6
LNTH Lantheus	4.3578 of 5 stars	3.5	1.0	4.2	2.3	2.5	1.9
NUVL Nuvalent	2.2176 of 5 stars	3.5	2.0	0.0	1.5	3.3	0.0
OCUL Ocular Therapeutix	3.625 of 5 stars	3.4	1.0	4.1	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.49% Upside
LNTH Lantheus	3.00	Buy	$132.67	67.95% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	52.92% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$17.00	104.08% Upside

Current Analyst Ratings Breakdown

Latest OCUL, NUVL, LNTH, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/3/2025	AXSM Axsome Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$185.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/22/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/14/2025	AXSM Axsome Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/7/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$200.00 ➝ $180.00
5/6/2025	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $165.00
5/6/2025	AXSM Axsome Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$160.00 ➝ $162.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.14	N/A	N/A	$1.18 per share	87.19
LNTH Lantheus	$1.53B	3.56	$7.10 per share	11.13	$15.65 per share	5.05
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
OCUL Ocular Therapeutix	$63.72M	20.83	N/A	N/A	$2.01 per share	4.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.49	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	22.44	12.52	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.15	N/A	N/A	N/A	-323.09%	-59.92%	-41.98%	8/6/2025 (Estimated)

Latest OCUL, NUVL, LNTH, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
LNTH Lantheus	0.49	5.74	5.46
NUVL Nuvalent	N/A	14.48	14.48
OCUL Ocular Therapeutix	0.26	10.22	10.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
LNTH Lantheus	99.06%
NUVL Nuvalent	97.26%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
LNTH Lantheus	1.50%
NUVL Nuvalent	10.20%
OCUL Ocular Therapeutix	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	155.64 million	Optionable

OCUL, NUVL, LNTH, and AXSM Headlines

Recent News About These Companies

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

June 18 at 10:18 PM | ophthalmologytimes.com

Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) PT at $16.25

June 18 at 2:23 AM | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) shareholders have earned a 33% CAGR over the last three years

June 17 at 11:55 AM | uk.finance.yahoo.com

Assenagon Asset Management S.A. Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 17 at 3:37 AM | marketbeat.com

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

June 16, 2025 | globenewswire.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Brokerages

June 15, 2025 | marketbeat.com

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

June 11, 2025 | ophthalmologytimes.com

Courier Capital LLC Boosts Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 8, 2025 | marketbeat.com

Ameriprise Financial Inc. Purchases 40,700 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 3, 2025 | marketbeat.com

Ocular Therapeutix closes enrollment in phase 3 SOL-R clinical trial for wet AMD

June 2, 2025 | ophthalmologytimes.com

Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $3.54 Million Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

June 2, 2025 | marketbeat.com

What is HC Wainwright's Forecast for OCUL Q1 Earnings?

June 2, 2025 | marketbeat.com

H.C. Wainwright maintains $15 target on Ocular Therapeutix stock

May 31, 2025 | investing.com

Voloridge Investment Management LLC Has $286,000 Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 31, 2025 | marketbeat.com

Millennium Management LLC Takes $3.82 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

May 31, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Holdings Lessened by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at HC Wainwright

May 30, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,862 Shares

May 29, 2025 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Insider Peter Kaiser Sells 2,974 Shares

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, NUVL, LNTH, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$102.89 +1.29 (+1.27%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$101.66 -1.22 (-1.19%)

As of 06/18/2025 07:31 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Lantheus NASDAQ:LNTH

$78.99 +1.07 (+1.37%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$79.62 +0.63 (+0.80%)

As of 06/18/2025 07:29 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Nuvalent NASDAQ:NUVL

$75.53 -0.53 (-0.70%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$75.55 +0.02 (+0.03%)

As of 06/18/2025 04:39 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$8.33 +0.03 (+0.36%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$8.33 0.00 (0.00%)

As of 06/18/2025 04:04 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time